Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs

June 11, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search